Processing

Please wait...

Settings

Settings

1. WO2007002172 - HIV-1 PROTEASE INHIBITORS

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

We claim:
1. A compound, or a pharmaceutically acceptable salt thereof, of formula I:



wherein, independently for each occurrence,
X1 is absent, -O-, -S- or -NR-;
X2 is absent, -O-, -S- or -NR-;
R1 is -OH, -SH or -NHR;
R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;
R2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R5 is hydrogen, alkyl, (cycloalkyl)alkylj (amino)alkyl, (amido)alkyl, (keto)alkyl,
cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
and
the stereochemical configuration at any stereocenter is R, S, or a mixture of these
configurations;

provided that when X1 is absent; R3 is no
; wherein R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

2. The compound of claim 1, wherein X1 is absent.

3. The compound of claim 1, wherein X2 is absent.
4. The compound of claim 1, wherein X1 is absent; and X2 is absent.
5. The compound of claim 1, wherein R1 is -OH.
6. The compound of claim 1, wherein R2 is aralkyl or heteroaralkyl.
7. The compound of claim 1, wherein R2 is aralkyl.
8. The compound of claim I3 wherein R3 is alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
9. The compound of claim 1, wherein R3 is aryl or heteroaryl.
10. The compound of claim 1, wherein R4 is alkyl, aryl or heteroaryl.
11. The compound of claim 1, wherein R5 is alkyl, (cycloalkyl)alkyl, (amino)alkyl,
(amido)alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
12. The compound of claim 1, wherein R5 is alkyl, (cycloalkyl)alkyl or (heterocyclyl)alkyl.

13. The compound of claim 1, wherein X1 is absent; X2 is absent; R1 is -OH; R2 is aralkyl; R3 is aryl or heteroaryl; R4 is alkyl, aryl or heteroaryl; and R5 is alkyl, (cycloalkyl)alkyl or
(heterocyclyl)alkyl.
14. A compound, or a pharmaceutically acceptable salt thereof, of formula II:



wherein, independently for each occurrence,
X1 is absent or -O-;
R3 is alkyl, alkenyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R4 is aryl, heteroaryl, aralkyl or heteroaralkyl; and R6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl;

provided that when X1 is absent; R3 is no
wherein R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

15. The compound of claim 14, wherein X1 is absent.
16. The compound of claim 14, wherein R3 is alkenyl, (amino)alkyl, (amido)alkyl,
(keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
17. The compound of claim 14, wherein R3 is aryl or heteroaryl.
18. The compound of claim 14, wherein R4 is alkyl, aryl or heteroaryl.
19. The compound of claim 14, wherein R6 is alkyl, (cycloalkyl)alkyl, (amino)alkyl,
(amido)alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
20. The compound of claim 14, wherein R6 is alkyl, (cycloalkyl)alkyl or (heterocyclyl)alkyl.

21. The compound of claim 14, wherein R3 is



22. The compound of claim 14, wherein R4 is


23. The compound of claim 14, wherein R6 is



24. The compound of claim 14, wherein X1 is absent; and R3 is


25. The compound of claim 14, wherein X1 is absent; R3 is



26. The compound of claim 14, wherein X1 is absent; R3 is
CH3

27. The compound of claim 14, wherein R4 is


28. The compound of claim 14, wherein X1 is absent; R3 is


9. A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of





30. A compound, or a pharmaceutically acceptable salt thereof, selected from the group

consisting of





31. A compound, or a pharmaceutically acceptable salt thereof, of formula III:





wherein, independently for each occurrence,
X1 is absent, -0-, -S- or -NR-;
X2 is absent, -0-, -S- or -NR-;
R1 is -OH, -SH or -NHR;
R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;
R2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R5 is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;
R7 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl,
cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
and
the stereochemical configuration at any stereocenter is R, S, or a mixture of these
configurations;

provided that when X1 is absent; R3 is no
o
; wherein R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

and provided that when X2 is absent; R4 is not
or
; wherein
R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

32. The compound of claim 31, wherein X1 is absent.
33. The compound of claim 31 , wherein X2 is absent.
34. The compound of claim 31, wherein X1 is absent; and X2 is absent.
35. The compound of claim 31 , wherein R1 is -OH.
36. The compound of claim 31, wherein R2 is aralkyl or heteroaralkyl.
37. The compound of claim 31 , wherein R2 is aralkyl.

38. The compound of claim 31 , wherein R3 is alkenyl, (amino)alkyl, (amido)alkyl,
(keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
39. The compound of claim 31 , wherein R3 is aryl or heteroaryl.
40. The compound of claim 31 , wherein R4 is alkyl, aryl or heteroaryl.
41. The compound of claim 31 , wherein R5 is hydrogen.
42. The compound of claim 31 , wherein R7 is alkyl, (cycloalkyl)alkyl, (amino)alkyl,
(amido)alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
43. The compound of claim 31 , wherein R7 is alkyl, (cycloalkyl)alkyl or aralkyl.
44. The compound of claim 31, wherein X1 is absent; X2 is absent; R1 is -OH; R2 is aralkyl; R3 is aryl or heteroaryl; R4 is alkyl, aryl or heteroaryl; R5 is hydrogen; and R7 is alkyl,
(cycloalkyl)alkyl or aralkyl.
45. A compound, or a pharmaceutically acceptable salt thereof, of formula IV:



wherein, independently for each occurrence,
X1 is absent or -O-;
R3 is alkyl, alkenyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R4 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl,
aralkyl or heteroaralkyl; and
R7 is alkyl, cycloalkyl, (cycloalkyl)alkyl or aralkyl;

provided that when X1 is absent; R3 is no
wherein R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

and provided that when X2 is absent; R4 is no
; wherein
R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

46. The compound of claim 45, wherein X1 is absent.
47. The compound of claim 45, wherein R3 is (amino)alkyl, (amido)alkyl, (keto)alkyl,
cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

48. The compound of claim 45, wherein R4 is aryl, (amino)alkyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl.
49. The compound of claim 45, wherein R7 is alkyl, cycloalkyl or (cycloalkyl)alkyl.
50. The compound of claim 45, wherein X1 is absent; and R3 is (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
51. The compound of claim 45, wherein X1 is absent; R3 is (amino)alkyl, (amido)alkyl,
(keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R4 is aryl, (amino)alkyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl; and R7 is alkyl, cycloalkyl or (cycloalkyl)alkyl.

52. The compound of claim 45, wherein R3 is



53.



54. The compound of claim 45, wherein R7 is
or

55. The compound of claim 45, wherein X1 is absent; and R3 is


56. The compound of claim 45, wherein X1 is absent; R3 is


57. The compound of claim 45, wherein X1 is absent; R3 is


58. The compound of claim 45, wherein R4 is


59. The compound of claim 45, wherein Xj is absent; R3 is



60. A compound, or a pharmaceutically acceptable salt thereof, selected from the group

consisting o


-86-


61. A compound, or a pharmaceutically acceptable salt thereof, of formula V:



wherein, independently for each occurrence,
X1 is absent, -O-, -S- or -NR-;
X2 is absent, -O-, -S- or -NR-;
Ri is -OH, -SH or -NHR;
R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;
R2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R4 is alkyl, cycloalkyl, lieterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, arallcyl or heteroaralkyl;
R5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl,
cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
and
the stereochemical configuration at any stereocenter is R, S, or a mixture of these
configurations;

provided that when X1 is absent; R3 is no
; wherein R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

and provided that when X2 is absent; R4 is no
A; wherein
R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

62. The compound of claim 61, wherein X1 is absent.
63. The compound of claim 61, wherein X1 is -O-.
64. The compound of claim 61, wherein X2 is absent.
65. The compound of claim 61, wherein X1 is absent or -O-; and X2 is absent.
66. The compound of claim 61, wherein R1 is -OH.
67. The compound of claim 61, wherein R2 is aralkyl or heteroaralkyl.
68. The compound of claim 61 , wherein R2 is aralkyl.
69. The compound of claim 61, wherein R3 is alkenyl, (amino)alkyl, (amido)alkyl,
(keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.
70. The compound of claim 61, wherein R3 is heterocyclyl.

71. The compound of claim 61 , wherein R4 is (heterocyclyl)alkyl.
72. The compound of claim 61 , wherein R5 is alkyl.
73. The compound of claim 61, wherein X1 is absent or -O-; X2 is absent; Ri is OH; R2 is aralkyl; R3 is heterocyclyl; R4 is alkyl, aryl or heteroaryl; and R5 is alkyl.
74. A compound, or a pharmaceutically acceptable salt thereof, of formula VI:



wherein, independently for each occurrence,
X1 is absent or -O- ;
R1 is -OH or -NH2;
R3 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R4 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl; and
R6 is alkyl, cycloalkyl, or aryl;

provided that when Xi is absent; R3 is not
or
; wherein R3 A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

and provided that when X2 is absent; R4 is no
or ; wherein


R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

75. The compound of claim 74, wherein R1 is -OH.
76. The compound of claim 74, wherein Rj is -NH2.
77. The compound of claim 74, wherein X1 is -O.
78. The compound of claim 74, wherein R3 is heterocyclyl.

79. The compound of claim 74, wherein R3 is

80. The compound of claim 74, wherein X1 is -O-; and R3 is heterocyclyl.


82. The compound of claim 74, wherein R4 is heterocyclyl.
83. The compound of claim 74, wherein R6 is alkyl.
84. The compound of claim 74, wherein R6 is -CH(CH3)2.
85. A compound, or a pharmaceutically acceptable salt thereof, of formula VII:



wherein, independently for each occurrence,
X1 is absent, -0-, -S- or -NR-;
X2 is absent, -O-, -S- or -NR-;
Ri is -OH, -SH or -NHR;
R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;
R2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl,
cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
and
the stereochemical configuration at any stereocenter is R, S, or a mixture of these
configurations;

provided that when X1 is absent; R3 is
R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

and provided that when X2 is absent; R4 is no

R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

86. The compound of claim 85, wherein X1 is absent.
87. The compound of claim 85, wherein X2 is absent.
88. The compound of claim 85, wherein X1 is absent; and X2 is absent.
89. The compound of claim 85, wherein R1 is -OH or -NH2.
90. The compound of claim 85, wherein R2 is aralkyl or heteroaralkyl.
91. The compound of claim 85, wherein R2 is aralkyl.
92. The compound of claim 85, wherein R3 is alkenyl, (amino)alkyl, (amido)alkyl,
(keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

93. The compound of claim 85, wherein R3 is (amido)alkyl or heterocyclyl.
94. The compound of claim 85, wherein R4 is (amido)alkyl or heterocyclyl.
95. The compound of claim 85, wherein R5 is alkyl or aryl.
96. The compound of claim 85, wherein X1 is absent; X2 is absent; R1 is -OH; R2 is aralkyl; R3 is (amido)alkyl or heterocyclyl; R4 is (amido)alkyl or heterocyclyl; and R5 is alkyl or aryl.
97. A compound, or a pharmaceutically acceptable salt thereof, of formula VIII:



wherein, independently for each occurrence,
X1 is absent or -O-;
R3 is alkyl, alkenyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;
R4 is aryl, heteroaryl, aralkyl or heteroaralkyl; and
R6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl;

provided that when X1 is absent; R3 is no
; wherein R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl,
cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

and provided that when X2 is absent; R4 is no
; wherein
R3A is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

98. The compound of claim 97, wherein X1 is absent.
99. The compound of claim 97, wherein R3 is (amino)alkyl, (amido)alkyl or heterocyclyl.

100. The compound of claim 97, wherein R3 is

101. The compound of claim 97, wherein R4 is (amino)alkyl, (amido)alkyl or heterocyclyl.

102. The compound of claim 97, wherein R4 is



103. The compound of claim 97, wherein R6 is alkyl or aryl.

104. The compound of claim 97, wherein R6 is

105. The compound of claim 102, wherein R3 is
; R4 is


, Or
; and R6 is

106. A compound, or a pharmaceutically acceptable salt thereof, selected from the group



107. A pharmaceutical composition, comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of any one of claims 1-106.
108. A method for treating an HIV infection, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of any one^of claims 1-106.

109. A method for treating an HIV infection, comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 107.

110. The method of claim 108, wherein the compound is administered as part of a highly active antiretroviral therapy (HAART) regimen.
111. The method of claim 109, wherein the pharmaceutical composition is admini stered as part of a highly active antiretroviral therapy (HAART) regimen.
112. The method of any one of claims 108-111, further comprising administering a second therapeutic agent.
113. The method of claim 112, wherein the second therapeutic agent is a non-nucleoside
reverse transcriptase inhibitor (NNRTI), a nucleoside reverse transcriptase inhibitor
(NRTI), a nucleotide reverse transcriptase inhibitor, an entry inhibitor, an integrase
inhibitor, a fusion inhibitor, a protease inhibitor, or an inhibitor of a metabolic enzyme.

114. The method of claim 112, wherein the second therapeutic agent is selected from the group consisting of efavirenz (Sustiva™), nevirapine (Viramune™), delavirdine
(Rescriptor™), AZT (zidovudine, Retrovir™)/3TC (lamivudine, Epivir™), d4T (stavudine, Zerit™)/3TC, ddl (didanosine, Videx™/VidexEC™), ddC (zalcitabine,
Hivid™), d4T, tenofovir (Viread™), and enfuvirtide (Fuzeon™).
115. The method of claim 112, wherein the second therapeutic agent is selected from the group consisting of amprenavir (Agenerase®; APV), tipranavir (Aptivus®; TPV),
indinavir (Crixivan®; IDV), saquinavir (Invirase®; SQV), lopinavir and ritonavir
(Kaletra®; LPV), fosamprenavir (Lexiva®; FPV), ritonavir (Norvir®; RTV), atazanavir (Reyataz®; ATZ), nelfinavir (Viracept®; NFV), brecanavir, and darunavir.
116. The method of claim 112, wherein the second therapeutic agent is ritonavir (Kaletra®; LPV).
117. The method of claim 112, wherein the second therapeutic agent is selected from the group consisting of zidovudine (AZT; Azidothymidine; Retrovir®), didanosine
(Dideoxyinosine; ddl; Videx®), zalcitabine (Dideoxycytidine; ddC; Hivid®), lamivudine (3TC; Epivir®), stavudine (2',3'-didehydro-3'-deoxythymidine; D4T; Zerit®), abacavir succinate (1592U89 succinate; Ziagen® ABC), Combivir® (lamivudine & zidovudine; (-)-3TC & AZT), and Trizivir® (abacavir & lamivudine & zidovudine; ABC & (-)-3TC & AZT) .
118. The method of claim 112, wherein the second therapeutic agent is selected from the group consisting of nevirapine (BI-RG-587; Viramune®), delavirdine (BHAP; U-90152; Rescriptor®), and (efavirenz; DMP-266; Sustiva®).
119. The method of claim 112, wherein the second therapeutic agent is T-20 (Fuzeon®;
Enfuvirtide; DP-178; Pentafuside; GP41 127-162 AA).
120. The method of claim 112, wherein the second therapeutic agent is TMCCl 14.
121. The method of claim 120, further comprising administering a reverse transcriptase
inhibitor.
122. The method of claim 112, wherein the second therapeutic agent is lupinavir.
123. The method of claim 122, further comprising administering a reverse transcriptase
inhibitor.